Champions OncologyvsJohnson & Johnson

CSBR and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CSBR

Champions Oncology, Inc.

$4.68

Value $65M

-0.64%
CSBR's page

Champions Oncology (CSBR) has a market value of $65M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, CSBR moved -31.2% and JNJ +47.5%. Dividend yield: CSBR none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CSBR$65M

    JNJ$681B

    JNJ is 10,472 times CSBR

  • Revenue, 12 months

    CSBR$61M

    JNJ$99.3B

    JNJ is 1,638 times CSBR

  • Net income, 12 months

    CSBR-$1.1M

    JNJ$16.1B

  • Operating margin

    CSBR-1.7%

    JNJ–

  • ROIC

    CSBR-20.4%

    JNJ12.4%

    32.8 points apart

  • P/E

    CSBR–

    JNJ42.3

  • Dividend yield

    CSBR0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CSBR-52.6%

    JNJ+98.6%

    151.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CSBR-52.6%

JNJ+98.6%

5010015020020222023202420252026
Returns by period
PeriodCSBRWith dividendsJNJWith dividends
1 year since November 14, 2025-31.2%Price -31.2%+47.5%Price +44.2%
3 years since November 16, 2023-16.3%-5.8% a yearPrice -16.3%+105.0%+27.0% a yearPrice +88.2%
5 years since November 15, 2021-52.6%-13.9% a yearPrice -52.6%+98.6%+14.7% a yearPrice +72.8%
10 years since November 16, 2016+170.5%+10.5% a yearPrice +170.5%+218.6%+12.3% a yearPrice +142.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CSBRChampions OncologyJNJJohnson & Johnson

Valuation

CSBRJNJ
Valuation
Price$4.68$282.55
Market value$65M$681B
Enterprise value (EV)$61M$708B
P/E–42.3
P/E, 5-year median–21.9
P/B16.78.4
EV/EBIT–39.9
Free cash flow yield–3.0%

Results and growth

CSBRJNJ
Results and growth
Revenue, 12 months$61M$99.3B
Net income, 12 months-$1.1M$16.1B
Free cash flow, 12 months-$6.1M$20.6B
Earnings per share, 12 months-$0.08$6.59
Revenue growth, year on year4.4%6.1%
Revenue growth a year, past+7.7%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CSBRJNJ
Margins and returns on capital
Gross margin49.8%67.6%
Operating margin-1.7%–
Net margin-1.9%16.2%
ROIC-20.4%12.4%
ROE-28.7%19.7%

Balance sheet

CSBRJNJ
Balance sheet
Cash$4.4M$17.2B
Total debt$10M$44.7B
Net debt / EBITDA-11.41.1
Interest cover–18.0×

Dividends and buybacks

CSBRJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CSBR or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Champions Oncology or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 10,472.1 times Champions Oncology ($65M), at today's prices.

How did CSBR and JNJ stock do over the last 10 years?

Since November 16, 2016, CSBR's price moved +170.5% and JNJ's +142.8%. With dividends: CSBR +170.5% (+10.5% a year), JNJ +218.6% (+12.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, CSBR or JNJ?

The dividend yield at today's price is none for Champions Oncology and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Champions Oncology or Johnson & Johnson?

Over the last twelve months, the net margin was -1.9% for Champions Oncology and 16.2% for Johnson & Johnson, and the operating margin -1.7% and –. Revenue was $61M and $99.3B.

Which is the better investment, Champions Oncology or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.